130972-89-3

Basic information

• Product Name: tert-butyl 4-hydroxy-3-MethoxybenzylcarbaMate
• Synonyms: tert-butyl 4-hydroxy-3-MethoxybenzylcarbaMate
• CAS NO: 130972-89-3
• Molecular Formula: C₁₃H₁₉NO₄
• Molecular Weight: 253.29426
• Mol File: 130972-89-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-hydroxy-3-MethoxybenzylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-hydroxy-3-MethoxybenzylcarbaMate(130972-89-3)
• EPA Substance Registry System: tert-butyl 4-hydroxy-3-MethoxybenzylcarbaMate(130972-89-3)

Safety Data

• Hazardous Substances Data: 130972-89-3(Hazardous Substances Data)

Usage

General Description

Tert-butyl 4-hydroxy-3-methoxybenzylcarbamate is a chemical compound commonly used as a pharmaceutical intermediate or as a building block in the synthesis of various pharmaceutical substances. It is a derivative of carbamic acid and contains a tert-butyl group, a hydroxy group, and a methoxy group attached to a benzene ring. tert-butyl 4-hydroxy-3-MethoxybenzylcarbaMate may have potential medicinal properties and is often used in the development of drugs for various therapeutic applications. Additionally, it may be used as an antioxidant or stabilizer in certain products due to its hydroxy and methoxy groups. Overall, tert-butyl 4-hydroxy-3-methoxybenzylcarbamate is a versatile chemical with diverse potential applications in the pharmaceutical and industrial sectors.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 7149-10-2 vanillylamine hydrochloride 
• 81259-54-3 4-benzyloxy-3-methoxybenzaldehyde oxime 
• 1196-92-5 Vanillylamin 

Downstream Products

• 130972-90-6 tert-butyl N-[4-(2-bromoethoxy)-3-methoxybenzyl]carbamate 
• 184003-57-4 [4-(3-Bromo-propoxy)-3-methoxy-benzyl]-carbamic acid tert-butyl ester 
• 289903-56-6 4-(2-azidoethoxy)-3-methoxybenzylisothiocyanate 
• 289903-50-0 tert-butyl N-[4-(2-azidoethoxy)-3-methoxybenzyl]carbamate 
• 289903-58-8 2,2-Dimethyl Propionic Acid 2-{3-[4-(2-Azidoethoxy)-3-methoxybenzyl]thioureido Methyl}-3-(3,4-dimethylphenyl)propyl ester 
• 289903-60-2 2,2-Dimethyl Propionic Acid 2-{3-[4-(2-Azidoethoxy)-3-methoxybenzyl]thioureido Methyl}-3-(4-t-butylphenyl)propyl Ester 
• 139693-27-9 4-(2-phthalimidoethoxy)-3-methoxybenzylisothiocyanate 
• 130972-91-7 {4-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethoxy]-3-methoxy-benzyl}-carbamic acid tert-butyl ester 
• 184003-58-5 {4-[3-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-propoxy]-3-methoxy-benzyl}-carbamic acid tert-butyl ester 

Relevant articles and documents

Capsaicin derivatives with nitrothiophene substituents: Design, synthesis and antibacterial activity against multidrug-resistant S. aureus

To address the emergency caused by multi-drug resistant Staphylococcus aureus, a series of novel capsaicin derivatives with nitrothiophene substituents have been designed and evaluated for the antibacterial activities against S. aureus Newman and multidrug-resistant strains (NRS-1, NRS-70, NRS-100, NRS-108, and NRS-271). The structure-activity relationship was further revealed. Compound 13c, 13f, and 13g were highly active against staphylococcal growth, with minimal inhibition concentration (MIC) values of 0.39–1.56 μg/mL. The oxadiazole-derived compound 21, a bioisostere of ester 13f, is the most potent candidate for anti-growth of five multidrug-resistant S. aureus strains with MICs of 0.20–0.78 μg/mL, which is more active compared with vancomycin in vitro. Notably, these anti-staphylococcal compounds are much less cytotoxic to the normal kidney epithelial cell line (HK293T).

The SAR analysis of TRPV1 agonists with the α-methylated B-region

A series of TRPV1 agonists with amide, reverse amide, and thiourea groups in the B-region and their corresponding α-methylated analogues were investigated. Whereas the α-methylation of the amide B-region enhanced the binding affinities and potencies as agonists, that of the reverse amide and thiourea led to a reduction in receptor affinity. The analysis indicated that proper hydrogen bonding as well as steric effects in the B-region are critical for receptor binding.

UROTENSIN II RECEPTOR ANTAGONISTS

The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.